.jpg)
Cantor Fitzgerald analyst Louise Chen assigned a Buy rating to Nabriva (NASDAQ: NBRV) today and set a price target of $16. The company’s shares closed on Friday at $5.43, close to its 52-week low of $4.39.
Chen commented:
“We expect a transformational 12-18 months for Nabriva and think it is a good time to take another look at the shares. Positive data for Lefamulin should drive upwards earnings revisions to levels not yet reflected in consensus expectations. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12- month price target of $16.”
According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.8% and a 42.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.
Currently, the analyst consensus on Nabriva is Strong Buy and the average price target is $14.67, representing a 170.2% upside.
In a report issued on May 8, Needham also reiterated a Buy rating on the stock with a $18 price target.
See today’s analyst top recommended stocks >>
Based on Nabriva’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.26 million. In comparison, last year the company had a GAAP net loss of $15.22 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic available for systemic administration in humans.
